You searched for advanced - Page 2 of 5 - Breast Cancer Resources for Healthcare Professionals | Wiley Knowledge Hub

Skip to content

German Resources
Italian Resources
About
Stay Up To Date

BREAST CANCER

Home
Videos
Infographics
- Video Infographics
- Infographics
Conference Coverage
- ASCO 2025
- SABCS 2024
  - Video Highlights
  - Conference Report [Multiple Languages Available]
Articles
Faculty

BREAST CANCER

Search for:

Home
Videos
Infographics
- Video Infographics
- Infographics
Conference Coverage
- ASCO 2025
- SABCS 2024
  - Video Highlights
  - Conference Report [Multiple Languages Available]
Articles
Faculty

German Resources
Italian Resources
About
Stay Up To Date

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

Article / By Mike Echalaz

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) Read More »

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Article / By Mike Echalaz

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 Read More »

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Article / By Mike Echalaz

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Read More »

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

Article / By Mike Echalaz

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) Read More »

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

Article / By Mike Echalaz

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer Read More »

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Article / By Mike Echalaz

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies Read More »

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Article / By Mike Echalaz

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Read More »

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Article / By Mike Echalaz

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis Read More »

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy

Article / By Mike Echalaz

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy Read More »

[Italian] Key Insights on Early and Metastatic Breast Cancers

Infographic / By Stacy Prettyman

[Italian] An overview of early and advanced breast cancers with special focus on staging, molecular subtypes, risk factors and risk stratification, risk of developing breast cancer, and therapeutic options

[Italian] Key Insights on Early and Metastatic Breast Cancers Read More »

← Previous 1 2 3 … 5 Next →

This educational resource is supported by Eli Lilly.

Eli Lilly has had no influence over the content or selection of the Editorial Panel.

Knowledge Hub

Home
Videos
Infographics
Conference Coverage
Articles
Faculty

About

About
Stay Up To Date
Privacy Policy
Terms & Conditions

Copyright © 2025 John Wiley & Sons, Inc. Alle Rechte vorbehalten.

Cookie Preferences

Username or Email Address

Password

Remember Me

Lost your password?

Start typing and press enter to search

Search...

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.